View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species
|No technical papers have yet appeared (Nov 2016) but the Hanmi patent  includes binned IC50 data for 150 analogues. Olmutinib is recorded as having <50nM for inhibition of EGFR with L858R/T790M mutation, two other mutations and 100-1000nM for wild type EGFR . In these biochemical assays olmutinib was more selective for the mutant EGFR than erlotinib. Inhibition data for cancer cell lines is also provided, with GI50 values of <50nM vs. cells with DelE746_A750 or L858R/T790M EGFR mutations, and >1000nM for cells with wild type EGFR.